Applications

 

Thanks to the specific technology developed by ERYtech Pharma, a powerful platform has been validated:

  • to develop new products with long circulating action with no release of the compounds:
    - Bio-reaction into the red cells (Graspa®)
    - Oxygen-hemoglobin affinity reduction (Grara) 
  • to rapidly target specific cells involved in the erythrophagocytosis (Kupffer cells, dendritic cells, macrophages): Immune Modulation Platform
    - Immuno-Inflammation (Gr-Rnai)
    - Immune Tolerance Induction (Gr-Tol)
    - Immuno Stimulation (Gr-Vax).

 

 

Erytech Pharma
Last Update 27/01/2012
2005 ERYtech Inc. All Rights Reserved | Terms and Conditions | Contact Us